3D-Matrix withdraws application of hemostatic peptide TDM-621

The putative application of the peptide is in gastrointestinal bleedings but verification of hemostatic effects seems to require further confirmation. Fiscal year earnings forecarst was revised in excess of 10 billion Yen.

3D Matrix press release, March 13, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny